# NIAID-VRC-Research, Development, and Production to Support Ebola Bispecific Antibody Development

> **NIH NIH N01** · LEIDOS BIOMEDICAL RESEARCH, INC. · 2022 · $2,765,029

## Abstract

The NIAID mission and scope includes rapidly responding to infectious disease outbreaks and preparing for future pandemics through clinical product development, reagent production, and manufacturing. In following this mission, the VRC has prioritized development of vaccines and antibodies targeting Ebola that may lead to prevention and/or therapeutic treatment. Specifically, the VRC seeks to develop and manufacture Ebola bispecific antibody products.

## Key facts

- **NIH application ID:** 10722435
- **Project number:** 75N91019D00024-0-759102200015-1
- **Recipient organization:** LEIDOS BIOMEDICAL RESEARCH, INC.
- **Principal Investigator:** CHRIS CASE
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $2,765,029
- **Award type:** —
- **Project period:** 2022-09-19 → 2027-09-18

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10722435

## Citation

> US National Institutes of Health, RePORTER application 10722435, NIAID-VRC-Research, Development, and Production to Support Ebola Bispecific Antibody Development (75N91019D00024-0-759102200015-1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10722435. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*